Pancreatic Cancer Research

ResearcherKumamoto Regional Medical CenterActive in the last 2 years

Hidetoshi Nitta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1875-4789; OpenAlex author ID A5014010146. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2015: 1 paper · 2016: 4 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. An 8-Year Survivor after Three-Time Hepatectomies for Metachronous Pancreatic Adenocarcinoma Liver Metastases. Co-author DOI 10.70352/scrj.cr.25-0242↗
  2. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… Co-author PMID 37293171↗
  3. Efficacy of Staging Laparoscopy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14037↗
  4. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Unde… Co-author DOI 10.1097/mpa.0000000000001146↗
  5. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Co-author DOI 10.1007/s00595-015-1238-8↗
  6. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000624↗
  7. EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Rapid growing cystic ovarian metastasis from pancreatic cancer. Co-author DOI 10.1111/jgh.13164↗
  8. Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by t… Co-author PMID 27069182↗
  9. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Co-author DOI 10.1111/cas.12732↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirohisa Okabe · 4 shared papers, 2015–2026 · strength 0.50
  2. Naoki Umezaki · 2 shared papers, 2018–2026 · strength 0.38
  3. Masahiko Hirota · 2 shared papers, 2016–2026 · strength 0.35
  4. Daisuke Hashimoto · 5 shared papers, 2016–2020 · strength 0.35
  5. Hiroki Sugita · 1 shared paper, 2026 · strength 0.30
  6. Toshiro Masuda · 1 shared paper, 2026 · strength 0.30
  7. Akira Chikamoto · 5 shared papers, 2015–2018 · strength 0.29
  8. Shigeki Nakagawa · 3 shared papers, 2015–2023 · strength 0.29
  9. Hideo Baba · 4 shared papers, 2016–2020 · strength 0.27
  10. Tatsunori Miyata · 2 shared papers, 2020–2023 · strength 0.26
  11. Hiromitsu Hayashi · 3 shared papers, 2015–2023 · strength 0.26
  12. Kota Arima · 3 shared papers, 2016–2020 · strength 0.21
  13. Takanobu Yamao · 2 shared papers, 2018–2020 · strength 0.18
  14. Norio Uemura · 1 shared paper, 2023 · strength 0.16
  15. Hideo Baba · 1 shared paper, 2023 · strength 0.16
  16. Kosuke Mima · 1 shared paper, 2023 · strength 0.16
  17. Kazuki Matsumura · 1 shared paper, 2023 · strength 0.16
  18. Hiroki Sato · 1 shared paper, 2023 · strength 0.16
  19. Zhao Liu · 1 shared paper, 2023 · strength 0.16
  20. Katsunori Imai · 2 shared papers, 2015–2018 · strength 0.12
  21. Takayoshi Kaida · 2 shared papers, 2016 · strength 0.10
  22. Yuki Kitano · 1 shared paper, 2020 · strength 0.10
  23. Kensuke Yamamura · 1 shared paper, 2020 · strength 0.10
  24. Hideo Baba · 2 shared papers, 2015–2016 · strength 0.10
  25. Hideo Baba · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.